Marco Maria Brughera

CIK: 0001589776

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (25.0%)

Position reduction

Option Exercises (M)1 (25.0%)

Derivative conversions

Awards (A)2 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

FENC

FENNEC PHARMACEUTICALS INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

FENC
FENNEC PHARMACEUTICALS INC.
Sep 15, 2026
Exercise(M)
Direct
15.5K shares at avg. $2.11$33K
FENC
FENNEC PHARMACEUTICALS INC.
Sep 15, 2026
Sale(S)
Direct
15.5K shares at avg. $10.29$160K
FENC
FENNEC PHARMACEUTICALS INC.
Jun 10, 2026
Award(A)
Stock Option
Direct
20K shares at avg. $8.70-
FENC
FENNEC PHARMACEUTICALS INC.
Jun 3, 2025
Award(A)
Stock Option
Direct
20K shares at avg. $7.88-

		Type	Shares	Price		Ownership
Sep 15, 2026	FENC FENNEC PHARMACEUTICALS INC.	Exercise(M)	15,545	$2.11	$32,800	Direct
Sep 15, 2026	FENC FENNEC PHARMACEUTICALS INC.	Sale(S)	15,545	$10.29	$159,958	Direct
Jun 10, 2026	FENC FENNEC PHARMACEUTICALS INC.	Award(A) Stock Option	20,000	$8.70	-	Direct
Jun 3, 2025	FENC FENNEC PHARMACEUTICALS INC.	Award(A) Stock Option	20,000	$7.88	-	Direct

1-4 of 4 transactions

About Brughera Marco Maria

Brughera Marco Maria (SEC CIK 0001589776) files insider reports with the SEC as Director of FENNEC PHARMACEUTICALS INC. (FENC).

Signal8 holds 3 ownership filings by Brughera Marco Maria, all Form 4s, filed between Jun 4, 2025 and Sep 16, 2026. Those filings report 4 transactions, from Jun 3, 2025 to Sep 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Brughera Marco Maria's filings is in RESEARCH TRIANGLE PARK, NC.

Recent filings by Brughera Marco Maria

Sep 15, 2026: Option exercise of FENC shares (Form 4, code M).
Sep 15, 2026: Open-market sale of FENC shares (Form 4, code S).
Jun 10, 2026: Grant or award of FENC derivative securities (Form 4, code A).
Jun 3, 2025: Grant or award of FENC derivative securities (Form 4, code A).

Other insiders filing for FENNEC PHARMACEUTICALS INC. (FENC)

Evans Terry L, Chief Commercial Officer
Sayad Pierre Sargis, Chief Medical Officer
Hackman Jeffrey S., Chief Executive Officer
Cioffi Christiana Marie, Chief Strategy Officer
Andrade Robert, CHIEF FINANCIAL OFFICER
Raykov Rosty, Officer

How to read Form 4 transaction codes